Exercise acts as a drug; the pharmacological benefits of exercise
TRPA1 channels in the vasculature
Selective block of KATP channels: why the anti-diabetic sulphonylureas and rosiglitazone have more in common than we thought
Rosiglitazone selectively inhibits KATP channels by acting on the KIR6 subunit
Activation of endothelial and epithelial KCa2.3 calcium-activated potassium channels by NS309 relaxes human small pulmonary arteries and bronchioles
Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors
Chondroprotective and anti-inflammatory role of melanocortin peptides in TNF-α activated human C-20/A4 chondrocytes
Modulation of PAR1 signalling by benzimidazole compounds
Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia
Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation
1-Dehydro-[10]-gingerdione from ginger inhibits IKKβ activity for NF-κB activation and suppresses NF-κB-regulated expression of inflammatory genes
Characterization of DDRI-18 (3,3′-(1 H ,3′ H -5,5′-bibenzo[ d ]imidazole-2,2′-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response
Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats
Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors
Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice
Cannabinoid CB1 receptors mediate the effects of corticotropin-releasing factor on the reinstatement of cocaine seeking and expression of cocaine-induced behavioural sensitization
Both α1- and β1-adrenoceptors in the bed nucleus of the stria terminalis are involved in the expression of conditioned contextual fear
Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety